Can Hormone Therapy Start During Perimenopause?

Why Perimenopause Is a Valid Starting Point for Hormone Therapy

Perimenopause marks the stretch of fluctuating ovarian function before menstruation stops entirely. Estradiol levels swing unpredictably during this phase, producing hot flashes, sleep disruption, mood instability, and cycle irregularity that can persist for years. Starting hormone therapy here is not premature. The 2022 NAMS position statement explicitly endorses HT initiation for symptomatic perimenopausal women, provided the benefit-risk profile is favorable.

The "Timing Hypothesis" Supports Early Initiation

The timing hypothesis proposes that estrogen therapy confers cardiovascular benefit when begun close to menopause onset, but may pose risk when started decades later. Data from the WHI age-stratified reanalysis supports this: women aged 50 to 59 who received conjugated equine estrogen alone had a 48% reduction in coronary heart disease risk (HR 0.52, 95% CI 0.29 to 0.96) compared with placebo [1]. The same therapy started in women aged 70 to 79 showed no benefit and a trend toward harm.

What the KEEPS and ELITE Trials Added

The Kronos Early Estrogen Prevention Study (KEEPS) randomized 727 recently menopausal women (within 36 months of their final period) to low-dose oral or transdermal estradiol versus placebo. After 4 years, KEEPS found no significant increase in carotid intima-media thickness, coronary calcium, or cardiovascular events in either treatment arm [2]. The ELITE trial (N=643) reinforced this by showing that estradiol reduced carotid intima-media thickness progression only when started within 6 years of menopause, not when started 10 or more years later [3]. These findings give clinicians confidence that perimenopausal initiation sits firmly in the low-risk window.

Who Qualifies for HT During Perimenopause

Not every perimenopausal woman needs prescription hormones. Treatment is indicated when symptoms meaningfully disrupt daily life and no absolute contraindications exist.

Symptom-Based Criteria

The Endocrine Society clinical practice guideline recommends HT for moderate-to-severe vasomotor symptoms (hot flashes, night sweats), sleep disruption tied to hormonal shifts, and genitourinary changes like vaginal dryness or dyspareunia [4]. Mild symptoms that respond to lifestyle changes do not require HT.

Absolute Contraindications

Women with a personal history of breast cancer, active liver disease, unexplained vaginal bleeding, a history of venous thromboembolism (VTE) unrelated to surgery, or known thrombophilia are generally not candidates for systemic HT. The American College of Obstetricians and Gynecologists (ACOG) notes that low-dose vaginal estrogen may still be an option for genitourinary symptoms in some of these populations, but systemic therapy is off the table.

The FSH Question

Some women ask whether they need an elevated FSH level before starting. They do not. The 2022 NAMS statement clarifies that perimenopause is diagnosed clinically (cycle irregularity plus symptoms in a woman over 40), not by a single hormone level. FSH fluctuates so widely during perimenopause that a "normal" result does not exclude the diagnosis [5].

Which Hormones Are Prescribed and in What Forms

Choosing the right formulation during perimenopause involves balancing symptom severity, bleeding patterns, thrombotic risk, and patient preference.

Estrogen Options

Transdermal estradiol (patches, gels, or sprays delivering 0.025 to 0.05 mg/day) is the preferred first-line route for most perimenopausal women. The Cochrane review on transdermal versus oral estrogen found that transdermal delivery avoids hepatic first-pass metabolism and does not raise VTE risk the way oral formulations do [6]. A 2017 nested case-control study in The BMJ (N=80,396 VTE cases) reported that transdermal estradiol carried no statistically significant increase in VTE risk (adjusted OR 0.93, 95% CI 0.87 to 1.01), while oral estrogen raised the odds by roughly 50% [7].

Oral estradiol (0.5 to 1 mg/day) remains an option for women at low thrombotic risk who prefer a pill. Conjugated equine estrogens are less commonly prescribed today, though they constituted the estrogen arm in the original WHI.

Progestogen Requirements

Any woman with an intact uterus who takes systemic estrogen must also take a progestogen to prevent endometrial hyperplasia. Options include oral micronized progesterone (100 to 200 mg nightly), the levonorgestrel-releasing intrauterine system (LNG-IUS, 52 mg), or cyclic medroxyprogesterone acetate [8]. The PEPI trial demonstrated that micronized progesterone was the only progestogen that did not blunt estrogen's favorable effect on HDL cholesterol, making it a popular first choice [9].

Continuous Versus Cyclic Regimens

During perimenopause, cyclic HT (estrogen daily plus progestogen for 12 to 14 days per month) is common because it allows a predictable withdrawal bleed. Women can transition to a continuous combined regimen (both hormones daily, no planned bleed) once they are closer to or past their final menstrual period. Switching too early often causes breakthrough bleeding that triggers unnecessary workups.

What to Expect When Starting HT in Perimenopause

The first weeks of hormone therapy involve an adjustment window. Setting realistic expectations prevents premature discontinuation.

Timeline for Symptom Relief

Hot flashes typically decrease within 2 to 4 weeks. Sleep quality usually improves over a similar timeframe. Mood stabilization may take 4 to 8 weeks, and vaginal tissue changes require 8 to 12 weeks of consistent estrogen exposure before full benefit appears. Dr. JoAnn Manson, professor of medicine at Harvard and principal investigator in the WHI, has noted: "Most women experience meaningful hot flash relief within the first month of therapy, but mood and cognitive benefits may take longer to manifest" [10].

Breast Tenderness and Bloating

Mild breast tenderness and fluid retention are the most commonly reported early side effects. They tend to resolve within 4 to 6 weeks. Lowering the estrogen dose temporarily or switching from oral to transdermal delivery can help if they persist.

Irregular Bleeding

Perimenopausal women on cyclic HT may experience unpredictable spotting during the first 3 to 6 months. Bleeding that occurs outside the expected withdrawal window, is unusually heavy, or persists beyond 6 months should prompt transvaginal ultrasound and potentially endometrial biopsy to rule out pathology [11].

Monitoring and Follow-Up Schedule

Safe HT use requires structured follow-up, especially during the first year.

Baseline Assessments

Before prescribing, clinicians should obtain a blood pressure reading, fasting lipid panel, mammogram (if not done within the past year), and a clinical breast exam. The NAMS position statement recommends checking thyroid function if symptoms overlap with hypothyroidism and obtaining a baseline endometrial thickness measurement via ultrasound if the patient has risk factors for endometrial pathology [5].

First-Year Check-Ins

A follow-up visit at 3 months evaluates symptom response, bleeding patterns, and side effects. Dose adjustment happens here if needed. A second visit at 6 to 12 months includes repeat blood pressure and a check on mammogram scheduling. Annual reassessment of the benefit-risk ratio is standard practice.

Long-Term Considerations

The 2022 NAMS statement removed the previous recommendation to use "the lowest dose for the shortest time" and replaced it with individualized, ongoing reassessment [5]. For women who started HT in perimenopause and remain symptomatic, there is no mandatory stop date. Dr. Stephanie Faubion, medical director of NAMS, stated: "Arbitrary time limits on hormone therapy are not supported by the evidence. The decision to continue should be revisited annually with a thorough benefit-risk discussion" [12].

How Perimenopause HT Differs from Postmenopausal HT

The distinction is not just semantic. Prescribing patterns and clinical reasoning shift depending on where a woman falls in the menopausal transition.

Dose Selection

Perimenopausal women often still produce variable amounts of endogenous estradiol. This means they may need lower exogenous doses than a woman who is 5 years past her last period. Starting with the lowest available transdermal dose (0.025 mg/day) and titrating up based on symptom response is standard practice.

Cycle Management

Postmenopausal women on continuous combined HT expect no bleeding. Perimenopausal women on cyclic regimens expect a withdrawal bleed each month. This distinction matters because any bleeding in a postmenopausal woman on continuous HT is abnormal and demands evaluation, while periodic bleeding in a perimenopausal woman on cyclic HT is expected.

Contraception Overlap

Perimenopause does not guarantee infertility. Women who need both symptom relief and contraception may benefit from a hormonal IUD (which provides endometrial protection) plus transdermal estradiol, or from combined oral contraceptives rather than traditional HT until they are confirmed menopausal. The ACOG committee opinion on contraception in perimenopause notes that low-dose combined oral contraceptives are safe for nonsmoking women up to age 50 and can manage both vasomotor symptoms and cycle irregularity simultaneously [13].

Risks to Weigh Before Starting

No therapy is without trade-offs. The key is ensuring the patient and clinician both understand the magnitude of each risk.

Breast Cancer

The WHI estrogen-plus-progestogen arm showed an attributable risk of approximately 8 additional breast cancer cases per 10,000 women-years of use after a mean 5.6 years of follow-up [14]. The estrogen-only arm (for women without a uterus) showed no increase in breast cancer, and a subsequent WHI follow-up analysis published in JAMA reported a statistically significant 23% reduction in breast cancer incidence in the estrogen-only group over 20 years of cumulative follow-up [15]. Risk varies by progestogen type; synthetic progestogens carry higher risk than micronized progesterone, though head-to-head randomized comparisons remain limited.

Venous Thromboembolism

Oral estrogen increases VTE risk by approximately 1.5-fold. Transdermal estradiol does not appear to carry this risk, based on multiple observational studies including a French E3N cohort analysis of over 80,000 postmenopausal women [7]. For women with obesity (BMI 30 or above) or a family history of VTE, transdermal delivery is the clear default.

Stroke

The absolute increase in stroke risk with HT is small in younger women. The WHI showed an additional 8 strokes per 10,000 women-years in the estrogen-plus-progestogen arm, but this was largely driven by women over 60 [14]. In the 50-to-59 age group, the increase was not statistically significant.

Practical Steps to Get Started

A woman who suspects she is perimenopausal and wants to explore HT should take the following concrete steps.

Step 1: Track Symptoms

Keep a 2-week log of hot flash frequency, sleep quality, mood, and menstrual cycle dates. Quantified symptoms give the prescribing clinician a clear baseline.

Step 2: Schedule a Focused Visit

Request an appointment specifically for menopause management. General wellness visits rarely leave enough time to discuss HT in depth. Bring the symptom log and a list of current medications.

Step 3: Discuss Formulation Preferences

Ask about transdermal estradiol plus micronized progesterone as a starting combination. If contraception is also needed, discuss the option of an LNG-IUS for endometrial protection plus a low-dose estradiol patch.

Step 4: Commit to Follow-Up

Agree to a 3-month reassessment. Most dose adjustments happen early, and unmonitored HT is unnecessarily risky.

The median age of natural menopause in the United States is 51.4 years, according to the Study of Women's Health Across the Nation (SWAN), meaning the average perimenopausal window opens in the mid-40s [16]. Women experiencing new symptoms in that window should know that waiting for a confirmed menopause diagnosis is not required before starting therapy.